Sci­wind gets li­cens­ing deal with Sanofi for meta­bol­ic dis­ease can­di­dates; Im­mu­ni­ty­Bio and En­Gene­IC reach deal for nano cell tech

Sci­wind Bio­sciences an­nounced last night that it signed an ex­pan­sive li­cense agree­ment with Sanofi to de­vel­op and com­mer­cial­ize Sanofi’s long-last­ing glu­cose-de­pen­dent in­sulinotrop­ic polypep­tide (GIP) re­cep­tor ag­o­nists. Ac­cord­ing to Sci­wind, the lead can­di­date is cur­rent­ly un­der pre­clin­i­cal de­vel­op­ment.

The deal cov­ers all ap­plic­a­ble in­di­ca­tions for the mol­e­cule. Sci­wind plans to de­vel­op the lead GIP re­cep­tor ag­o­nist as part of com­bi­na­tion with XWoo3, its GLP-1 pep­tide can­di­date which is cur­rent­ly be­ing eval­u­at­ed in Phase II stud­ies to po­ten­tial­ly treat di­a­betes, obe­si­ty and NASH.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER